These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15501371)

  • 1. Cost estimation when time and resources are limited: the Brief DATCAP.
    French MT; Roebuck MC; McLellan AT
    J Subst Abuse Treat; 2004 Oct; 27(3):187-93. PubMed ID: 15501371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP).
    Salomé HJ; French MT; Miller M; McLellan AT
    Drug Alcohol Depend; 2003 Aug; 71(2):195-206. PubMed ID: 12927658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program.
    Roebuck MC; French MT; McLellan AT
    J Subst Abuse Treat; 2003 Jul; 25(1):51-7. PubMed ID: 14512108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).
    French MT; Dunlap LJ; Zarkin GA; McGeary KA; McLellan AT
    J Subst Abuse Treat; 1997; 14(5):445-55. PubMed ID: 9437614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of family-based substance abuse treatment.
    Morgan TB; Crane DR
    J Marital Fam Ther; 2010 Oct; 36(4):486-98. PubMed ID: 21039660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rehabilitation of the mentally ill].
    Berger M
    Psychiatr Prax; 2006 Apr; 33(3):103-4. PubMed ID: 16583347
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of alternative staff time data collection methods on drug treatment service cost estimates.
    Zarkin GA; Dunlap LJ; Wedehase B; Cowell AJ
    Eval Program Plann; 2008 Nov; 31(4):427-35. PubMed ID: 18640722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of cost-benefit analysis in integration projects on drug addiction].
    Ates T; Langer B; Erbas B; Tretter F; Wehner B
    Gesundheitswesen; 2005 Feb; 67(2):159-62. PubMed ID: 15747208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic benefits of substance abuse treatment: findings from Cuyahoga County, Ohio.
    Koenig L; Siegel JM; Harwood H; Gilani J; Chen YJ; Leahy P; Stephens R
    J Subst Abuse Treat; 2005; 28 Suppl 1():S41-50. PubMed ID: 15797638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes.
    Sindelar JL; Jofre-Bonet M; French MT; McLellan AT
    Drug Alcohol Depend; 2004 Jan; 73(1):41-50. PubMed ID: 14687958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.